Sector News

Medtronic-Covidien to shed 150 jobs at Dublin centre

November 5, 2015
Life sciences

The medical device company Medtronic-Covidien is to shed 150 jobs at its contact centre in Dublin, according to the Communications Workers Union (CWU).
At a meeting with senior management on Monday, staff were told the jobs would be relocated to Poland next June. The contact centre offers support services in a number of languages to European clients.

The CWU has criticised the US firm for refusing to engage with it on the ground at the Cherrywood facility.

“Unfortunately the shocking news was just delivered yesterday and they [staff] are just coming to terms with it,” CWU head of organising Ian McArdle told The Irish Times.

“Quite understandably the staff are in a state of shock. They would have felt that their jobs were secure. . .”

The company could not be reached for comment last night. Mr McArdle said he expected further details to emerge at a meeting between union and staff tonight and appealed to the company to engage.

Last January, Medtronic became the largest company based in Ireland when it began trading on the New York Stock Exchange.

Following its $49.9 billion acquisition of Dublin-domiciled surgical supplies group Covidien, the Minneapolis-based business moved its corporate headquarters to Ireland.

Source: The Irish Times

comments closed

Related News

May 4, 2024

Novartis acquires Mariana in $1.75bn deal to strengthen radioligand portfolio

Life sciences

Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.

May 4, 2024

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Life sciences

The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.

May 4, 2024

Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn

Life sciences

Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.

How can we help you?

We're easy to reach